Lilly Partners with the National Cancer Institute to Accelerate Cancer Research through New Program under Cancer Moonshot Initiative (NYSE:LLY)

INDIANAPOLIS, Oct. 17, 2016 /PRNewswire/ -- With the global prevalence of new cancer cases expected to rise by 70 percent during the next two decades, representatives from government, academic, pharmaceutical and diagnostic companies are pooling their knowledge to accelerate treatments to patients.¹ Today, Eli Lilly and Company (NYSE: LLY) announced it will contribute cancer research data to the National Cancer Institute's Blood Profiling Atlas, an open access liquid biopsy database being created in response to Vice President Joe Biden's call to action and in alignment with the goals of the Cancer Moonshot initiative. The database is an effort to reduce the development time of effective and safe blood profiling diagnostic technologies.



Lilly Partners with the National Cancer Institute to Accelerate Cancer Research through New Program under Cancer Moonshot Initiative (NYSE:LLY)